Diagnos Inc
4D4A
Company Profile
Business description
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in the business segment of Healthcare services. The company has a business presence in Canada, the United States, Mexico, Chile, and others. The company's key revenue is derived from Canada.
Contact
7005 Taschereau Boulevard
Suite 265, Brossard
LongueuilQCJ4Z 1A7
CANT: +1 450 678-8882
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
31 March 2025
Employees
16
Stocks News & Analysis
stocks
Are investors missing the boat on this future ASX leader?
The market is underestimating the clear path to profitability.
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
stocks
Ask the analyst: Why have markets shunned APA Group?
Australia's premier gas infrastructure firm used to be a market darling, but its shares have taken a severe de-rating in recent years.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,471.80 | 39.90 | 0.47% |
| CAC 40 | 7,423.67 | 15.03 | 0.20% |
| DAX 40 | 20,271.33 | 138.48 | 0.69% |
| Dow JONES (US) | 42,518.28 | 221.16 | 0.52% |
| FTSE 100 | 8,201.54 | 22.65 | -0.28% |
| HKSE | 19,219.78 | 345.64 | 1.83% |
| NASDAQ | 19,044.39 | 43.71 | -0.23% |
| Nikkei 225 | 38,474.30 | 716.10 | -1.83% |
| NZX 50 Index | 12,879.60 | 4.78 | -0.04% |
| S&P 500 | 5,842.91 | 6.69 | 0.11% |
| S&P/ASX 200 | 8,231.00 | 39.10 | 0.48% |
| SSE Composite Index | 3,240.94 | 80.19 | 2.54% |